TNF and inflammatory bowel disease: Currently, the main biologics used in clinical IBD therapy are TNF-α inhibitors (Infliximab, Adalimumab, Certolizumab pegol, and Golimumab), anti-adhesion molecules (Natalizumab, Vedolizumab), anti-interleukin drugs (Ustekinumab, Risankizumab, and Brazikumab), Janus kinase inhibitors (Tofacitinib, Filgotinib, and Upadacitinib), and Sphingosine 1 Phosphate Receptor Modulator (Etrasimod and Ozanimod) [56].